Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.
Synergy time-kill studies against 40 methicillin-resistant Staphylococcus aureus (MRSA) strains of differing resistance phenotypes were conducted. Subinhibitory concentrations of telavancin were combined with sub-MIC concentrations of other antimicrobial agents that might be used in combination with telavancin to provide Gram-negative coverage. The highest incidence of synergy was found after 24 h with gentamicin (90% of strains), followed by ceftriaxone (88%), rifampin and meropenem (each 65%), cefepime (45%), and ciprofloxacin (38%) for combinations tested at or below the intermediate breakpoint for each agent.
Lin
Gengrong
G
Department of Pathology, Hershey Medical Center, Hershey, PA 17033, USA.
Pankuch
Glenn A
GA
Ednie
Lois M
LM
Appelbaum
Peter C
PC
D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000077723:Cefepime; D002443:Ceftriaxone / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D004357:Drug Synergism; D005839:Gentamicins / Q000494:pharmacology*; D000077427:Lipoglycopeptides; D000077731:Meropenem; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D013845:Thienamycins / Q000494:pharmacology; D013997:Time Factors
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D005839:Gentamicins; D000077427:Lipoglycopeptides; D013845:Thienamycins; D002939:Ciprofloxacin; D002443:Ceftriaxone; D000077723:Cefepime; D000077731:Meropenem; D010068:Oxacillin; D012293:Rifampin; C487637:telavancin